This $630,595 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research at Case Western Reserve University to evaluate the therapeutic potential of CHCHD10 antagonists for treating Alzheimer's disease. The key objectives are to: 1) assess the protective effects of CHCHD10 antagonists on Alzheimer's pathologies in mouse models and human neurons, and 2) delineate the interplay between CHCHD10, mitochondria-associated ER membranes (MAM), and mitophagy in ameliorating Alzheimer's disease. Through this research, the project aims to facilitate the development of CHCHD10 antagonists as a therapeutic strategy and provide mechanistic insights into CHCHD10-associated processes in Alzheimer's disease. The grant period runs from August 1, 2024 to April 30, 2029.
Generated 3/4/25, 5:41 AM